Summit Therapeutics plc Director/Pdmr Shareholding

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit Therapeutics" or the "Company") 
 
   Notification of Transaction of Persons Discharging Managerial 
Responsibilities 
 
   Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit 
Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic 
innovation, announces that it has received notification that on 7 
February 2020, Dr Elaine Stracker, a Non-Executive Director of the 
Company, was assigned for no consideration warrants to acquire a total 
of 2,099,207 ordinary shares by Maky Zanganeh and Associates, Inc. 
("MZA"). The Company has a consultancy agreement with MZA where Dr 
Stacker serves as General Counsel and Senior Vice President for 
Corporate Development. 
 
   Following the completion of this transfer, Dr Stracker has the following 
interest in the Company's ordinary shares: 
 
 
 
 
                                                                 Total Number 
                                                    Number of         of 
                                    Total number   Outstanding    Outstanding 
                                     of ordinary  Share Options    Warrants 
                                     shares held      Held           Held 
---------------  ---------------  --------------  -------------  ------------- 
                 Non-Executive 
Elaine Stracker   Director                   Nil      1,000,000      2,099,207 
---------------  ---------------  --------------  -------------  ------------- 
 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014. The person responsible for 
arranging for the release of this announcement on behalf of the Company 
is Richard Pye, Vice President, Investor Relations and Corporate 
Affairs. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics to 
treat infections caused by C. difficile, N. gonorrhoeae and 
Enterobacteriaceae and are using our proprietary Discuva Platform to 
expand our pipeline. For more information, visit www.summitplc.com and 
follow us on Twitter @summitplc. 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)              Tel:    [phone] 
Michelle Avery (US office)                                     [phone] 
 
Cairn Financial Advisers LLP (Nominated Adviser)    Tel:   [phone] 
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti 
 
 
 
 
 
   The information set out below is provided in accordance with the 
requirements of Article 19(3) of the Market Abuse Regulation (EU) No 
596/2014. 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------------------------- 
a)  Name                             (i) Dr Elaine Stracker 
    ------------------------  -------------------------------------------------------------- 
2   Reason for the notification 
    ---------------------------------------------------------------------------------------- 
a)  Position / status                (i) Non-Executive Director 
    ------------------------  -------------------------------------------------------------- 
b)  Initial notification /    Initial notification 
    Amendment 
    ------------------------  -------------------------------------------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------------------------- 
a)  Name                      Summit Therapeutics plc 
    ------------------------  -------------------------------------------------------------- 
b)  LEI                       213800NRW8AOMYMTBD89 
    ------------------------  -------------------------------------------------------------- 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    ---------------------------------------------------------------------------------------- 
a)  Description of the        Ordinary shares of 1 penny each 
    financial instrument, 
    type of instrument 
 
 
    Identification code       GB00BN40HZ01 
    ------------------------  -------------------------------------------------------------- 
b)  Nature of the             Assignment of warrants, for no consideration, to acquire 
    transactions               ordinary shares of one penny nominal value at a price 
                               of 22.1 pence per ordinary share 
    ------------------------  -------------------------------------------------------------- 
c)  Price(s) and volume(s)      Price(s)                   Volume(s) 
    ------------------------    -------------------------  ------------------------------- 
                                (i) nil                       (i) 2,099,207 
    ------------------------    -------------------------  ------------------------------- 
 
d)  Aggregated information 
     - Aggregated volume        2,099,207 warrants to acquire ordinary shares 
     - Price                    nil 
    ------------------------  -------------------------------------------------------------- 
e)  Date of the transactions  7 February 2020 
    ------------------------  -------------------------------------------------------------- 
f)  Place of the              Outside a trading venue 
    transactions 
    ------------------------  -------------------------------------------------------------- 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

February 10, 2020 09:15 ET (14:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.